Trifluridine/tipiracil (TAS-102) in combination with anti-EGFR re-challenge versus TAS-102 plus anti-VEGF in patients with mCRC who experienced first-line anti-EGFR-based chemotherapy.(ASCO GI 2024)
あなたは医師ですか。
[公開日] 2024.02.21[最終更新日] 2024.02.21